2nd Nov 2012 13:03
For immediate release | 2 November 2012 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR dealing: LTIP
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that on 1 November 2012 the Remuneration Committee granted the following conditional nil cost share awards based on a price of 385 pence per 0.2 pence Ordinary Share (the closing share price on 31 October 2012) to the Executive Directors and PDMRs of the Company under the Abcam plc Long-Term Incentive Plan (the "LTIP"):
Name | Number of 0.2 pence Ordinary Shares subject to the LTIP Award
| |
Executive Directors: | Jonathan Milner | 39,326 |
Jim Warwick | 30,100 | |
Jeff Iliffe | 28,495 | |
PDMRs: | Mark Bushfield | 14,164 |
Jane Cooke | 5,055 | |
Philippe Cotrel | 14,164 | |
Ed Ralph | 7,100 |
The shares subject to the LTIP Award will be released in three years time subject to continued employment and subject to a performance condition based on growth in earnings per share.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Andy Crossley - Corporate Broking
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 600 staff across its eight operating companies.
Abcam now has an online catalogue of over 98,900 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.
Related Shares:
ABC.L